Catch up with our 15th Perspectives by Bupa Global
The price of progress: What do advanced drugs mean for IPMI?
For our 15th episode of Perspectives by Bupa Global our speakers discussed advanced drugs and the implications they have on the IPMI industry. Our host, Carl Blake, welcomed speakers Dr Robin Clark- Medical Director Bupa Global & UK Insurance, Dr Rosemary Leonard - UK GP and Broadcaster, Andy Rallis - Human Capital Analytics, Aon Innovation Centre and Dr Emma Harvey - Independent Pharmaceutical Physician and Vice President, Faculty of Pharmaceutical Medicine.
From GLP-1s for obesity and diabetes to immunotherapies and gene treatments for cancer, a new wave of advanced therapies is moving rapidly from innovation to expectation. Driven by faster development cycles, advances in AI, and shifting public demand, these treatments are arriving quicker, costing more, and challenging traditional assumptions about coverage and care. But the implications for International Private Medical Insurance (IPMI) providers go far beyond cost.
These therapies raise complex questions about availability, regulation, clinical appropriateness, and long-term outcomes, particularly when their use evolves faster than policy frameworks or licensing norms.
